Her2-positive breast cancer Trials in Chicago, United States
Conditions / Her2-positive breast cancer / Chicago, United States
Research into Her2-positive breast cancer spans multiple therapeutic approaches and trial phases.
17 total trials for this combination
Showing top 10 of 17 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04886531 | Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | RECRUITING | PHASE2 |
| NCT05705401 | Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02213744 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | TERMINATED | PHASE2/PHASE3 |
| NCT05705401 | Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT04893109 | ATEMPT 2.0: Adjuvant T-DM1 vs TH | RECRUITING | — |
| NCT03975647 | A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06441890 | BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer | RECRUITING | PHASE2 |
| NCT05705401 | Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT04569747 | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer | RECRUITING | PHASE2 |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | RECRUITING | PHASE2 |